Inhaled simvastatin nanoparticles for inflammatory lung disease
Alaa S Tulbah1,2, Elvira Pisano3, Santo Scalia3
1Respiratory Technology, Woolcock Institute of Medical Research & Discipline of Pharmacology, Sydney Medical School, Sydney University, NSW 2037, Australia.
Nanomedicine (London, England)
|October 4, 2017
Summary
This study developed simvastatin nanoparticles (SV-NPs) for treating inflammatory lung diseases. These nanoparticles effectively reduced mucus production and suppressed inflammatory markers in cell models.
Area of Science:
- Nanotechnology
- Pulmonary Medicine
- Pharmacology
Background:
- Current inhaled treatments are insufficient for many lung diseases.
- There is a need for novel therapeutic strategies for inflammatory lung conditions.
Purpose of the Study:
- To develop a nanotechnology-based approach for delivering simvastatin via inhalation.
- To evaluate the anti-inflammatory and muco-inhibitory potential of simvastatin nanoparticles (SV-NPs) for lung disease treatment.
Main Methods:
- Simvastatin nanoparticles (SV-NPs) were fabricated using poly(lactic-co-glycolic) acid via solvent and anti-solvent precipitation.
- The stability of freeze-dried SV-NPs was assessed up to 9 months at 4°C.
Main Results:
- SV-NPs demonstrated stability for extended storage periods.
- Treatment with SV-NPs significantly reduced mucus production in inflammation epithelial cell models.
- SV-NPs effectively suppressed the expression of proinflammatory markers.
Conclusions:
- Nebulized SV-NPs show potential as a novel treatment for chronic pulmonary diseases.
- This nanotechnology offers a promising delivery system for anti-inflammatory compounds in lung disease therapy.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.0K
01:26COPD: Management Using Bronchodilators and Corticosteroids
888
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
888
01:23Inhaled Medications
880
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
880
01:20Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
545
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
545
01:30Asthma-IV: Nursing Management
3.9K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.9K